Physical Characterization and Innate Immunogenicity of Aggregated Intravenous Immunoglobulin (IGIV) in an In Vitro Cell-Based Model

[1]  S. Polumuri,et al.  Cell based assay identifies TLR2 and TLR4 stimulating impurities in Interferon beta , 2017, Scientific Reports.

[2]  M. Pallardy,et al.  Why the Immune System Should Be Concerned by Nanomaterials? , 2017, Front. Immunol..

[3]  Marisa K Joubert,et al.  Immunogenicity of Therapeutic Protein Aggregates. , 2016, Journal of pharmaceutical sciences.

[4]  Sandeep Kumar,et al.  The Effect of Small Oligomeric Protein Aggregates on the Immunogenicity of Intravenous and Subcutaneous Administered Antibodies. , 2015, Journal of pharmaceutical sciences.

[5]  D. Volkin,et al.  Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting. , 2015, Journal of pharmaceutical sciences.

[6]  M. Puig,et al.  Detection of Innate Immune Response Modulating Impurities in Therapeutic Proteins , 2015, PloS one.

[7]  W. Jiskoot,et al.  Small Amounts of Sub-Visible Aggregates Enhance the Immunogenic Potential of Monoclonal Antibody Therapeutics , 2015, Pharmaceutical Research.

[8]  T. Singer,et al.  The Immunogenicity of Antibody Aggregates in a Novel Transgenic Mouse Model , 2015, Pharmaceutical Research.

[9]  J. Mes,et al.  THP-1 cell line: an in vitro cell model for immune modulation approach. , 2014, International immunopharmacology.

[10]  W. Jiskoot,et al.  Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin. , 2014, Journal of pharmaceutical sciences.

[11]  Marie-Claude Djidja,et al.  Aggregation of Human Recombinant Monoclonal Antibodies Influences the Capacity of Dendritic Cells to Stimulate Adaptive T-Cell Responses In Vitro , 2014, PloS one.

[12]  Vibha Jawa,et al.  T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. , 2013, Clinical immunology.

[13]  T. Arora,et al.  Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics. , 2013, Journal of pharmaceutical sciences.

[14]  Yaping Tian,et al.  ATF4 is directly recruited by TLR4 signaling and positively regulates TLR4-trigged cytokine production in human monocytes , 2012, Cellular and Molecular Immunology.

[15]  E. Gelfand.  Intravenous immune globulin in autoimmune and inflammatory diseases. , 2012, The New England journal of medicine.

[16]  Jared S. Bee,et al.  The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective. , 2012, Journal of pharmaceutical sciences.

[17]  W. Jiskoot,et al.  Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice , 2012, mAbs.

[18]  H. Golding,et al.  Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo. , 2012, Vaccine.

[19]  S. Balu-Iyer,et al.  Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice. , 2012, Journal of pharmaceutical sciences.

[20]  E. Topp,et al.  Protein G, protein A and protein A-derived peptides inhibit the agitation induced aggregation of IgG. , 2012, Molecular pharmaceutics.

[21]  Huub Schellekens,et al.  Oxidized and Aggregated Recombinant Human Interferon Beta is Immunogenic in Human Interferon Beta Transgenic Mice , 2011, Pharmaceutical Research.

[22]  D. Verthelyi,et al.  Trace Levels of Innate Immune Response Modulating Impurities (IIRMIs) Synergize to Break Tolerance to Therapeutic Proteins , 2010, PloS one.

[23]  N. Chirmule,et al.  Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. , 2010, Clinical immunology.

[24]  M. Radosevich,et al.  Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance , 2010, Vox sanguinis.

[25]  Bruce Tangarone,et al.  Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcγ receptors , 2009, mAbs.

[26]  Hanns-Christian Mahler,et al.  Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.

[27]  Steven Kozlowski,et al.  Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. , 2009, Journal of pharmaceutical sciences.

[28]  Hanns-Christian Mahler,et al.  Shaken, not stirred: mechanical stress testing of an IgG1 antibody. , 2008, Journal of pharmaceutical sciences.

[29]  Maria L. D. Udan,et al.  Toll‐like receptors 2 and 4 mediate Aβ(1–42) activation of the innate immune response in a human monocytic cell line , 2007, Journal of neurochemistry.

[30]  M. Caulfield,et al.  Establishing Acceptance Criteria for Cell-Mediated-Immunity Assays Using Frozen Peripheral Blood Mononuclear Cells Stored under Optimal and Suboptimal Conditions , 2007, Clinical and Vaccine Immunology.

[31]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[32]  Y. Shoenfeld,et al.  Intravenous immunoglobulin , 2005, Clinical reviews in allergy & immunology.

[33]  Hanns-Christian Mahler,et al.  Induction and analysis of aggregates in a liquid IgG1-antibody formulation. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[34]  S. L. Yates,et al.  Amyloid β and Amylin Fibrils Induce Increases in Proinflammatory Cytokine and Chemokine Production by THP‐1 Cells and Murine Microglia , 2000, Journal of neurochemistry.

[35]  M. Weinand,et al.  Amyloid-β Induces Chemokine Secretion and Monocyte Migration across a Human Blood-Brain Barrier Model , 1998, Molecular medicine.

[36]  D. Lorton.  β-Amyloid-induced IL-1β release from an activated human monocyte cell line is calcium- and G-protein-dependent , 1997, Mechanisms of Ageing and Development.

[37]  T. H. Nguyen,et al.  Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation. , 1995, Biochemistry.

[38]  M. A. Andrade,et al.  Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network. , 1993, Protein engineering.

[39]  H. Fleit,et al.  The Human Monocyte‐Like Cell Line THP‐1 Expresses FcγRI and FCγRII , 1991 .

[40]  H. Ziltener,et al.  Aggregated immunoglobulin and Fc fragment of IgG induce IL-6 release from human monocytes. , 1990, Cellular immunology.

[41]  M. Daha,et al.  Degradation of Soluble Immunoglobulin Aggregates in Vitro by Monocytes from Normal Subjects and from Patients with Systemic Lupus Erythematosus , 1982, Scandinavian journal of immunology.

[42]  Shigeru Tsuchiya,et al.  Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1) , 1980, International journal of cancer.

[43]  T. Kinsella.  Enhancement of human lymphocyte transformation by aggregated human gamma globulin. , 1974, The Journal of clinical investigation.

[44]  C. Henney,et al.  Antibody production to aggregated human gamma-G-globulin in acquired hypogammaglobulinemia. , 1968, The New England journal of medicine.

[45]  H. Isliker,et al.  Intravenous Administration of Human γ‐Globulin * , 1962 .

[46]  C. Cudrici,et al.  The role of the complement system in innate immunity , 2005, Immunologic research.

[47]  D. Lorton.  beta-Amyloid-induced IL-1 beta release from an activated human monocyte cell line is calcium- and G-protein-dependent. , 1997, Mechanisms of ageing and development.

[48]  H. Fleit,et al.  The human monocyte-like cell line THP-1 expresses Fc gamma RI and Fc gamma RII. , 1991, Journal of leukocyte biology.

[49]  H. Isliker,et al.  Intravenous administration of human gamma-globulin. , 1962, Vox sanguinis.